Literature DB >> 18977659

Synthesis, tubulin assembly, and antiproliferative activity against MCF7 and NCI/ADR-RES cancer cells of 10-O-acetyl-5'-hydroxybutitaxel.

Haibo Ge1, Jianmei Wang, Margaret M Kayser, Richard H Himes, Gunda I Georg.   

Abstract

A highly efficient kinetic resolution of racemic cis-4-(2-tert-butyldimethylsilyloxy-1,1-dimethyl)ethyl-3-tert-butyldimethylsilyloxy-azetidin-2-one with 7-O-triethylsilylbaccatin III was carried out to furnish 10-O-acetyl-5'-hydroxybutitaxel after removal of the silyl protecting groups. The compound was 50% as active as paclitaxel in a tubulin assembly assay and showed significantly decreased activity against MCF7 cell proliferation compared to paclitaxel.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18977659      PMCID： PMC2636847          DOI： 10.1016/j.bmcl.2008.10.010

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  14 in total

1.  A systematic SAR study of C10 modified paclitaxel analogues using a combinatorial approach.

Authors:  Yanbin Liu; Syed M Ali; Thomas C Boge; Gunda I Georg; Samuel Victory; Jan Zygmunt; Rebecca T Marquez; Richard H Himes
Journal:  Comb Chem High Throughput Screen       Date:  2002-02       Impact factor: 1.339

2.  New highly active taxoids from 9 beta-dihydrobaccatin-9,10-acetals. Part 5.

Authors:  Yasuyuki Takeda; Kouichi Uoto; Michio Iwahana; Takeshi Jimbo; Motoko Nagata; Ryo Atsumi; Chiho Ono; Noriko Tanaka; Hirofumi Terasawa; Tsunehiko Soga
Journal:  Bioorg Med Chem Lett       Date:  2004-06-21       Impact factor: 2.823

3.  Synthesis of novel 3'-trifluoromethyl taxoids through effective kinetic resolution of racemic 4-CF3-beta-lactams with baccatins.

Authors:  I Ojima; J C Slater
Journal:  Chirality       Date:  1997       Impact factor: 2.437

Review 4.  Targeting microtubules for cancer chemotherapy.

Authors:  Jun Zhou; Paraskevi Giannakakou
Journal:  Curr Med Chem Anticancer Agents       Date:  2005-01

5.  Synthesis of docetaxel and butitaxel analogues through kinetic resolution of racemic beta-lactams with 7-O-triethylsilylbaccatin III.

Authors:  Haibo Ge; Jared T Spletstoser; Yan Yang; Margaret Kayser; Gunda I Georg
Journal:  J Org Chem       Date:  2007-02-02       Impact factor: 4.354

6.  Synthesis and interactions of 7-deoxy-, 10-deacetoxy, and 10-deacetoxy-7-deoxypaclitaxel with NCI/ADR-RES cancer cells and bovine brain microvessel endothelial cells.

Authors:  Haibo Ge; Veena Vasandani; Jacquelyn K Huff; Kenneth L Audus; Richard H Himes; Anna Seelig; Gunda I Georg
Journal:  Bioorg Med Chem Lett       Date:  2005-11-03       Impact factor: 2.823

7.  Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

Authors:  K A Gelmon; J Latreille; A Tolcher; L Génier; B Fisher; D Forand; S D'Aloisio; L Vernillet; L Daigneault; A Lebecq; M Besenval; E Eisenhauer
Journal:  J Clin Oncol       Date:  2000-12-15       Impact factor: 44.544

8.  Preparation of phenolic paclitaxel metabolites.

Authors:  H Park; M Hepperle; T C Boge; R H Himes; G I Georg
Journal:  J Med Chem       Date:  1996-07-05       Impact factor: 7.446

9.  The discovery of BMS-275183: an orally efficacious novel taxane.

Authors:  Harold Mastalerz; Donald Cook; Craig R Fairchild; Steven Hansel; Walter Johnson; John F Kadow; Byron H Long; William C Rose; James Tarrant; Mu-Jen Wu; May Quifen Xue; Guifen Zhang; Mary Zoeckler; Dolatrai M Vyas
Journal:  Bioorg Med Chem       Date:  2003-10-01       Impact factor: 3.641

Review 10.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.